With the sustainability and affordability of the US healthcare system in dire straits, now is the time for collaboration on new payment models, explained chief executive officers from a health plan and an insurer during a general session on the second day of America’s Health Insurance Plans’ Institute & Expo, held June 7-9 in Austin, Texas.
With the sustainability and affordability of the US healthcare system in dire straits, now is the time for collaboration on new payment models, explained chief executive officers from a health plan and an insurer during a general session on the second day of America’s Health Insurance Plans’ Institute & Expo, held June 7-9 in Austin, Texas.
The country needs to find a way to flatten spending as a percentage of growth domestic product (currently at 18%) without dampening the innovation coming out of laboratories, said David A. Ricks, president and CEO of Eli Lilly and Company.
“We’re embracing value-based pricing, which we see as 1 solution to achieve sustainability of consumer involvement, sustainability of spending, and increased innovation,” he said.
Eli Lilly and Harvard Pilgrim Health Care have a number of value-based agreements in place, one of which is unique because the price of the product—in diabetes—would change based on how it performs against other products in the same category.
“So, literally, the manufacturer putting our money where our mouth is,” Ricks said. "Not just making claims about superiority, but measuring outcomes and then adapting the value of the product versus other products in the class.”
While these agreements can be very beneficial, they are difficult to administer, which is what can hold organizations back, said Eric H. Schultz, president and CEO of Harvard Pilgrim Health Care. These contracts require bringing in clinical data, claims data, laboratory data, and other medical informatics in order for them to work.
Schultz added that his organization is interested in value-based payments because it allows them to get new products to patients faster. Value-based agreements have the most benefit with new products and payers and plans can share risk, Ricks said.
As the FDA strives to speed up its decision making to get medicines on the market and in patient hands faster, some drugs are being approved with less information available. Value-based pricing is a good response to deal with these newly approved drugs, Schultz explained, because plans can create a contract that it pays one price if the drug performs as well as the clinical trial and another price if the drug doesn’t perform as well.
Ricks and Schultz both agreed that value-based contracts won’t be needed for every drug. Starting the conversation on creating a value-based agreement is easiest when there is a high stakes category—there are a lot of people who could be impacted by the drug—and there are extensive medical consequences—the drug will lead to reduced costs for other issues. In addition, the earlier in a drug’s life cycle, the more likely these conversations are to happen.
“Earlier in the life cycle these [contracts] can play a stronger role,” Ricks said. “When we know a lot about it and it’s been backed up by real-world data, the utility is less clear.”
The contracts that Harvard Pilgrim has in place were all created because there was a “competitive event occurring," explained Schultz. The real challenge is getting pharmaceutical companies to sit down to make these deals when there isn’t another competing drug coming out, he added.
There remain differences in views between the drug companies and the health plans when it comes to pricing for drugs, and those differences will remain as long as the 2 sides aren’t meeting for conversations, Schultz said.
“We’re going to bump into each other and trip along the way, but we’re going to get there,” he believes.
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Study Links COVID-19 Pandemic to Rise in Neoadjuvant Chemotherapy for Ovarian Cancer in US
April 17th 2024There was greater use of neoadjuvant chemotherapy among US patients with ovarian cancer (OC) during the COVID-19 pandemic to reduce potential COVID-19 exposure and cancer treatment-related complications.
Read More
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More